HOME > BUSINESS
BUSINESS
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- Takeda’s Brigatinib Snags European Panel OK for 2nd Line ALK-Positive NSCLC
September 26, 2018
- Xtandi Gets CHMP Backing for Additional CRPC Indication
September 26, 2018
- DS-8201 Shows Positive PI Study Data for NSCLC: Daiichi Sankyo
September 26, 2018
- European Panel Backs Approval of Kyowa Kirin’s Mogamulizumab for Mycosis Fungoides, Sézary Syndrome
September 26, 2018
- Santen Files for Japan Approval of Anti-Allergy Eye Drop
September 26, 2018
- Daiichi Sankyo, Pfizer Grab Japan Approval for Herceptin Biosimilars
September 25, 2018
- AMED Backs Project for Development of Familial Adenomatous Polyposis Therapy Applied by FunPep, 3 Universities
September 25, 2018
- Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
September 25, 2018
- Daiichi Sankyo Teams Up with US Merck’s Subsidiary for Clinical Research of DS-8201/Keytruda Combo
September 25, 2018
- Astellas to Create New Business beyond Core Prescription Drug Business, Aims to Launch Several Products by FY2020
September 21, 2018
- Meiji Seika Pharma Commences Shipment of KM Biologics’ Flu Vaccine
September 21, 2018
- Roxadustat Hit Goal in CKD Patients with Anemia Not on Dialysis in Multinational PIII Study: Astellas
September 21, 2018
- Meiji Files Aricept Generic for Lewy Body Dementia to Win Full Indications
September 21, 2018
- Growing Number of Drug Makers Introducing LGBT-Friendly Policies
September 20, 2018
- Sosei, Allergan Suspend Joint Clinical Development of AD Therapy due to Unexpected Toxicology Findings
September 20, 2018
- Otsuka Pharmaceutical Factory Accuses AY Pharmaceuticals, Yoshindo for Patent Infringement on Transfusion Product
September 20, 2018
- Ono, US Bioventure Fate Therapeutics Hook Up for CAR-T Therapies
September 19, 2018
- Nichi-Iko to Copromote 5 Elmed Eisai Products from October
September 18, 2018
- Astellas Joins Hands with Gene Therapy Biotech for ALS Treatment Program
September 18, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
